Clinical Trial Update: Role of ROS and cAMP-PKA Biomarkers in ADPKD

View source ↗

Summary

Clinical trial update examining reactive oxygen species (ROS) and cAMP-PKA biomarkers in autosomal dominant polycystic kidney disease (ADPKD).

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Autosomal Dominant Polycystic Kidney Disease

Snippet

Sponsor: Mayo Clinic | Conditions: Autosomal Dominant Polycystic Kidney Disease | Status: ACTIVE_NOT_RECRUITING